tiprankstipranks
Trending News
More News >
Adaptimmune Therapeutics Plc. (ADAP)
:ADAP
US Market

Adaptimmune Therapeutics (ADAP) Income Statement

Compare
1,279 Followers

Adaptimmune Therapeutics Income Statement

Last quarter (Q2 2025), Adaptimmune Therapeutics's total revenue was $13.68M, a decrease of -89.33% from the same quarter last year. In Q2, Adaptimmune Therapeutics's net income was $-30.34M. See Adaptimmune Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 24Dec 23Dec 22Dec 21Dec 20
Total Revenue
$ 178.03M$ 60.28M$ 27.15M$ 6.15M$ 3.96M
Gross Profit
$ 177.96M$ 50.42M$ -100.58M$ -104.94M$ -87.61M
Operating Expenses
$ 246.72M$ 188.42M$ 191.11M$ 168.40M$ 137.36M
Depreciation and Amortization
$ 11.23M$ 9.84M$ 6.07M$ 6.57M$ 7.65M
EBITDA
$ -52.66M$ -128.20M$ -155.59M$ -155.68M$ -125.81M
Operating Income
$ -68.76M$ -138.04M$ -163.97M$ -162.25M$ -133.41M
Other Income/Expenses
$ 1.52M$ 25.50M$ -1.29M$ 4.95M$ 3.48M
Pretax Income
$ -67.24M$ -112.53M$ -162.96M$ -157.30M$ -129.93M
Net Income
$ -70.81M$ -113.87M$ -165.46M$ -158.09M$ -130.09M
Per Share Metrics
Basic EPS
$ -0.28$ -0.57$ -1.02$ -1.02$ -0.90
Diluted EPS
$ -0.28$ -0.57$ -1.02$ -1.02$ -0.90
Weighted Average Shares Outstanding
252.30M 201.07M 161.21M 155.81M 142.46M
Weighted Average Shares Outstanding (Diluted)
252.30M 201.07M 161.21M 155.81M 142.46M
Currency in USD

Adaptimmune Therapeutics Earnings and Revenue History